Inhibitor pamariksaan imun mangrupikeun kelas ubar anu ngalawan sistem imun awak pikeun ngalawan sél kanker. Nanging, kalolobaan pasien henteu ngaréspon kana terapi ieu. Aya kelas ubar anyar anu nargétkeun dua protéin anu aub dina ngahambat réspon imun awak ngalawan tumor.
Phase I of clinical trials has shown some exciting results, which were conducted in 19 patients suffering from kangker with the molecule M7824. These researchers are also undertaking trials with those suffering from kanker pancreatic and those infected with HPV.
There are many other trials and experiments being taken to treat and ngubaran kanker more effectively in different research institutes. This drug with a dual approach will be a boon in the pengobatan kanker, as with a single molecule, multiple therapies are included.
